TY  - CONF

T1  - Adjuvant bevacizumab in patients with melanoma at high
risk of recurrence (AVAST-M): preplanned interim results
from a multicentre, open-label, randomised controlled
phase 3 study

JO  - Lancet Oncology

UR  - https://eprints.whiterose.ac.uk/id/eprint/131249

UR  - https://doi.org/10.1016/S1470-2045(14)70110-X

PY  - 2017/05/20

AU  - Corrie P

AU  - Marshall A

AU  - Dunn J

AU  - Middleton MR

AU  - Nathan PD

AU  - Gore ME

AU  - Davidson D

AU  - Nicholson S

AU  - Kelly CG

AU  - Marples M

AU  - Danson S et al

ED  - 

DO  - DOI: 10.1016/S1470-2045(14)70110-X

PB  - Elsevier

VL  - 15

IS  - 6

SP  - 620

EP  - 630

Y2  - 2025/12/07

ER  -